Table 2.

Response to imatinib mesylate therapy (33 patients)

Response
No. response/no. evaluable (%)
CHR   11/11 (100)  
Cytogenetic response   26/27 (96)  
Complete   24/27 (89)  
Major
 		 19/21 (90)
 
Response
No. response/no. evaluable (%)
CHR   11/11 (100)  
Cytogenetic response   26/27 (96)  
Complete   24/27 (89)  
Major
 		 19/21 (90)
 
View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal